Company intelligence / Profile preview

EGEN

Huntsville, Alabama, United Statesegen.ai ↗

Ownership: Private
Development stage: Other

Overview

EGEN developed proprietary nanoparticle-based platforms for the targeted delivery of nucleic acid therapeutics. Its lead candidate, EGEN‑001, a gene therapy delivering interleukin‑12 via a nanocomplex system, showed good safety and encouraging efficacy in early clinical trials for recurrent ovarian cancer. Additional programs included RNAi therapies targeting microRNAs implicated in diseases such as pulmonary arterial hypertension.

Therapeutic areas: OncologyCardiovascular
Modalities: Gene therapySmall interfering RNASynthetic oligonucleotideNanoparticle
Industry: Biotech

Partnerships

Gynecological Oncology Group/National Cancer Institute collaboration on ovarian cancer trialsUniversity of South Alabama College of Medicine on PAH program

Beyond the preview

Go deeper on EGEN.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EGEN.

Explore the full profile